

There should be teaching programs which involve medical schools, community hospitals, and people that are knowledgeable in the medical fields to bring new information into practice. I have gone into some detail in the submitted paper.

Mr. Chairman, I have completed comment on my report to you. Briefly, I would hope:

One, that the former recommendations of the committee be implemented.

Two, that obesity be eliminated as a medical indication for the use of the agents under description in which the so-called anorectic property goes hand in hand with abuse potential.

Three, that over-the-counter nostrums advertised for the purpose of reducing obesity be eliminated that are continuing to be used by the citizens in a worthless manner for large sums of money.

Four, that the activities of the pharmaceutical industries be reviewed as to the ways in which they influence the practice of medicine.

Five, that consumer education be addressed.

And, finally, six, that although there is no easy solution, the manner by which the medical profession and the Federal Government can replace the pharmaceutical manufacturers as the principal purveyors of postgraduate medical training be sought.

I have suggested that this might be done through a traineeship-type of program for clinical pharmacologists. I believe that is the only way it can be done.

Senator NELSON. What is that?

Dr. PROUT. That this is the only way it might be done.

Senator NELSON. What might be done?

Dr. PROUT. That we might establish a method by which continuing medical education could be supported by something other than the pharmaceutical houses in order to prevent this continuing delusion of postgraduate medical education.

Thank you.

Senator NELSON. Thank you very much, Dr. Prout.

Our next witness is Dr. Sumner Yaffe, professor of clinical pharmacology and pediatrics, University of Pennsylvania, and director, Division of Clinical Pharmacology, Children's Hospital, Philadelphia, Pa.

Dr. Yaffe is also to represent Dr. Allen Goldman, associate professor of Pediatrics, University of Pennsylvania, and director, teratology unit, Children's Hospital, Philadelphia, Pa.¹

Please proceed, Dr. Yaffe.

STATEMENT OF SUMNER J. YAFFE, M.D., PROFESSOR OF CLINICAL PHARMACOLOGY AND PEDIATRICS, UNIVERSITY OF PENNSYLVANIA, AND DIRECTOR, DIVISION OF CLINICAL PHARMACOLOGY, CHILDREN'S HOSPITAL, PHILADELPHIA, PA.

Dr. YAFFE. Senator Nelson, Mr. Gordon, I am delighted to be here. I have two roles as I understand it this morning.

One is to introduce the testimony of Dr. Allen Goldman, who is associate professor of pediatrics in my institution at the University of

¹ See prepared statement of Dr. Goldman beginning at p. 14696. See also prepared statement of Dr. Yaffe beginning at p. 14967.